Literature DB >> 20800267

Characterisation and reproducibility of a human ex vivo model of thrombosis.

Andrew J Lucking1, Rajesh Chelliah, Alexander D Trotman, Thomas M Connolly, Giora Z Feuerstein, Keith A Fox, Nicholas A Boon, Juan J Badimon, David E Newby.   

Abstract

BACKGROUND: The Badimon chamber is a clinical ex vivo model of thrombosis that mimics flow conditions within the coronary circulation of man. The aims of this study were to characterise thrombus formation in the chamber and evaluate its reproducibility.
METHODS: Using blood from 24 healthy human volunteers, thrombus formation was assessed at low and high shear rates with porcine aortic tunica media as the thrombogenic substrate. Thrombus area was measured histomorphometrically. Reproducibility was assessed by paired measurements made both within and between days. Platelet activation was assessed before and at selected points within the extracorporeal circuit using flow cytometry, and fibrin content and distribution within the thrombus were assessed by immunohistochemistry.
RESULTS: Total thrombus area was highly reproducible within and between days in the low shear ([mean thrombus area, mean difference ± SEM] 8,018μm(2), 58±204μm(2) and 8,177μm(2), -154±168μm(2) respectively) and high shear chambers (11,802μm(2), -52±175μm(2) and 11,877μm(2), 220±181μm(2) respectively). Total thrombus area was greater in the high compared to the low shear chamber (11,970±285μm(2)versus 7,892±298μm(2); P<0.0001). Transit through the extracorporeal circuit did not result in platelet activation which was only detected after blood passed across the perfusion chambers (P=0.02 for platelet-monocyte aggregate formation and P=0.05 for P-selectin expression). Thrombus in the low shear chamber contained a greater proportion of fibrin (25.0±6.0% versus 8.3±1.6%, P<0.001).
CONCLUSIONS: The Badimon chamber provides a highly reproducible technique for the assessment of ex vivo platelet-rich thrombus formation in man.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20800267     DOI: 10.1016/j.thromres.2010.06.030

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

2.  Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial.

Authors:  Avais Jabbar; Lorna Ingoe; Simon Pearce; Azfar Zaman; Salman Razvi
Journal:  Trials       Date:  2015-03-25       Impact factor: 2.279

3.  PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.

Authors:  Simon J Wilson; Fraz A Ismat; Zhaoqing Wang; Michael Cerra; Hafid Narayan; Jennifer Raftis; Timothy J Gray; Shea Connell; Samira Garonzik; Xuewen Ma; Jing Yang; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-12-21       Impact factor: 8.311

4.  Fire Simulation and Cardiovascular Health in Firefighters.

Authors:  Amanda L Hunter; Anoop S V Shah; Jeremy P Langrish; Jennifer B Raftis; Andrew J Lucking; Mairi Brittan; Sowmya Venkatasubramanian; Catherine L Stables; Dominik Stelzle; James Marshall; Richard Graveling; Andrew D Flapan; David E Newby; Nicholas L Mills
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

5.  Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer.

Authors:  Jack P M Andrews; Christophe Portal; Tashfeen Walton; Mark G Macaskill; Patrick W F Hadoke; Carlos Alcaide Corral; Christophe Lucatelli; Simon Wilson; Ian Wilson; Gillian MacNaught; Marc R Dweck; David E Newby; Adriana A S Tavares
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-06-01       Impact factor: 6.875

6.  Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.

Authors:  Mohammed N Meah; Jennifer Raftis; Simon J Wilson; Vidya Perera; Samira M Garonzik; Bindu Murthy; J Gerry Everlof; Ronald Aronson; Joseph Luettgen; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

7.  Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.

Authors:  Simon J Wilson; Thomas M Connolly; Gary Peters; Atalanta Ghosh; Maureen Johnson; David E Newby
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

8.  Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.

Authors:  Claire S Whyte; Hadj Ahmed Mostefai; Kim M Baeten; Andrew J Lucking; David E Newby; Nuala A Booth; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.